Investors & Media

Press Releases


 
Press Releases
  Date Title View
May 18, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-217...
May 9, 2017
Phase 3 STATUS Trial of brexanolone in SRSE nearing completion of enrollment - expects top-line results in Q3 2017 Advancing SAGE-217 into Part B open-label Phase 2 trial in Parkinson's disease based on initial activity signal First patient dosed in placebo-controlled Phase 2 clini...
May 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on May 1, 2017, the Compensation Committee of Sage's Board of Directors granted a non-...
Apr 27, 2017
Lead compound from novel NMDA modulator product development platform Top-line results from single ascending dose trial expected in 2H 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicine...
Apr 25, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, May 9, 2017 at 4:30 ...
Apr 24, 2017
Key additions and promotions to team in commercial, development and regulatory roles CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorde...
Apr 19, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations for brexanolone (SAGE-547) and SAGE-217 at the American Academy of ...
Apr 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on April 3, 2017, the Compensation Committee of Sage's Board of Directors granted non-...
Mar 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017, the Compensation Committee of Sage's Board of Directors granted non-...
Feb 23, 2017
Continued momentum expected in 2017 with several programs anticipating clinical trial results this year, including two Phase 3 programs Phase 2 placebo-controlled study of SAGE-217 in major depressive disorder expected to begin in 1H 2017 First NMDA candidate, SAGE-718, pl...
1
... NextLast
= add release to Briefcase